Internal Medicine, Hematology & Oncology · Omaha, NE
NPI
1922286954
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
988102 Nebraska Medical Ctr
Omaha, NE, 68198
Phone (402) 559-5600
Groups this clinician bills Medicare through
Medicare paid, 2024
$45K
814 services
Medicare patients, 2024
204
Average age 70
Drug cost, 2024
$9.9M
2,270 prescriptions
Company payments, 2025
$481K
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mojtaba Akhtari was code 99214 (office e&m - established), 240 times for 70 patients. In total Mojtaba Akhtari billed 814 services in 18 codes, and Medicare paid $45K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-06-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 240 | 70 | $71.56 | $17K |
| 99212 Office E&M - Established | Facility | 235 | 89 | $25.68 | $6,034 |
| 99213 Office E&M - Established | Facility | 202 | 100 | $44.32 | $8,953 |
| 99233 Hospital E&M - Subsequent | Facility | 28 | 15 | $80.96 | $2,267 |
| 99215 Office E&M - Established | Facility | 19 | 18 | $115.44 | $2,193 |
| 99223 Hospital E&M - Initial | Facility | 15 | 15 | $128.84 | $1,933 |
By year: 2022 $35K for 684 services; 2023 $36K for 703 services; 2024 $45K for 814 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mojtaba Akhtari prescribed most often to Medicare patients was Acyclovir, with 182 prescriptions and refills. In total Mojtaba Akhtari wrote 2,270 Medicare prescriptions that cost $9.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 182 | 348 | 59 | $2,265 |
| Allopurinol Generic | 112 | 246 | 43 | $620 |
| Pomalyst Pomalidomide | 99 | 99 | 12 | $2.2M |
| Jakafi Ruxolitinib Phosphate | 70 | 70 | 11 | $1.2M |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 58 | 89 | 28 | $358 |
| Dexamethasone Generic | 56 | 98 | 17 | $1,764 |
| Ondansetron Hcl Generic | 55 | 57 | 25 | $672 |
| Mirtazapine Generic | 45 | 45 | 12 | $690 |
| Imbruvica Ibrutinib | 45 | 47 | Under 11 | $714K |
| Venclexta Venetoclax | 45 | 45 | Under 11 | $162K |
| Ondansetron Odt Ondansetron | 45 | 46 | 23 | $954 |
| Potassium Chloride Generic | 43 | 71 | 15 | $514 |
| Trazodone Hcl Generic | 42 | 47 | 12 | $125 |
| Gabapentin Generic | 39 | 53 | 13 | $497 |
| Diclofenac Sodium Generic | 37 | 37 | 11 | $1,584 |
Brand drugs: 609 claims; generic drugs: 1,661 claims; opioid claims: 110.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mojtaba Akhtari $481K ($481K in general payments such as food, travel and fees) from 21 companies. The largest payer was Incyte Corporation with $71K.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 45 | $71K |
| Syndax Pharmaceuticals, Inc. SNDX | 29 | $58K |
| Karyopharm Therapeutics Inc. KPTI | 22 | $48K |
| E.R. Squibb & Sons, L.L.C. BMY | 19 | $47K |
| Abbvie Inc. ABBV | 23 | $44K |
| Pfizer Inc. PFE | 20 | $42K |
| Astellas Pharma US Inc 4503.T | 21 | $37K |
| GlaxoSmithKline, LLC. GSK | 24 | $35K |
| Sobi, Inc SOBI.ST | 13 | $32K |
| PharmaEssentia USA Corporation 6446.TW | 11 | $18K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.